GlaxoSmithKline announced updated results for Tafinlar (dabrafenib) from the Phase 3 BREAK-3 study in patients with BRAF V600E mutant metastatic melanoma. Tafinlar is a selective BRAF inhibitor that blocks tumor cell growth through inhibition of some mutated forms of BRAF, including the BRAFV600 mutation.

BREAK-3 (BRF113683) is a randomized, open-label study comparing the efficacy, safety, and tolerability of dabrafenib to dacarbazine in patients with advanced or metastatic melanoma who harbour a BRAF V600E mutation. Patients with previously untreated BRAF V600E mutation-positive metastatic melanoma were randomized to receive dabrafenib or dacarbazine. The primary endpoint of the study was progression-free survival (PFS).

RELATED: First-in-Class Melanoma Drug Gets Accelerated Approval

Of those included in the dabrafenib arm, 45% were alive at two years compared to 32% of those who began treatment with dacarbazine.


Continue Reading

Tafinlar is already approved as monotherapy for the treatment of unresectable or metastatic melanoma with BRAF V600E mutation, as detected by an FDA-approved test. In combination with trametinib for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by a Food and Drug Administration-approved test.

For more information call (888) 825-5249 or visit GSK.com.